Drug Shortage Report for TEVA-PROCTOSONE

Last updated on 2021-01-14 History
Report ID 88222
Drug Identification Number 02226383
Brand name TEVA-PROCTOSONE
Common or Proper name PROCTOSONE
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) DIBUCAINE HYDROCHLORIDE HYDROCORTISONE FRAMYCETIN SULFATE ESCULIN
Strength(s) 5MG 5MG 10MG 10MG
Dosage form(s) OINTMENT
Route of administration RECTAL
Packaging size 15G
ATC code C05AA
ATC description AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
Reason for shortage Requirements related to complying with good manufacturing practices.
Anticipated start date
Actual start date 2019-07-02
Estimated end date Unknown
Actual end date
Shortage status Actual shortage
Updated date 2021-01-14
Company comments Alternate material supplier to be sourced and validated.
Health Canada comments
Tier 3 Status No
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v1 2019-07-02 English Compare
v2 2019-07-02 French Compare
v3 2019-07-03 English Compare
v4 2019-08-29 English Compare
v5 2019-08-29 French Compare
v6 2019-09-05 English Compare
v7 2019-09-05 French Compare
v8 2019-10-03 English Compare
v9 2019-10-03 French Compare
v10 2019-12-12 English Compare
v11 2019-12-12 French Compare
v12 2019-12-19 English Compare
v13 2019-12-19 French Compare
v14 2021-01-14 English Compare
v15 2021-01-14 French Compare

Showing 1 to 15 of 15